Translate to English

In the next few years, "the new rural cooperative medical care," the promotion of pilot scale rural medical market will reach 50 billion yuan. But how to explore this huge potential market, the third terminal is placed in front of a business problem.

If the passive waiting, only the loss of greater potential for the rural medical market, the third terminal is placed in front of a business problem. If the passive waiting, only the loss of greater opportunity. Wal-Mart founder of the world's business leaders have said a word Safari parent ? Walton: If everyone is taking the old road, and you choose a different path, it may have the golden opportunity. In recent years, many pharmaceutical companies to enter the rural market as a way to make a difference. companies to enter the rural market as a new economic growth point, they want to work hard to avoid the price of bloody Sisha blindly, but early yet to dig into the vast market. Such as South China Pharmaceutical cooperation with national authorities to promote the county and township medical training, education, primary care physicians, through the Such as South China Pharmaceutical cooperation with national authorities to promote the county and township medical training, education, primary care physicians, through the wall advertising, distribution of leaflets, exhibition and other activities focused on rural markets To increase the floor to strengthen advertising effectiveness. To make generic drugs sold to a new level. In addition, Dongsheng technology, including " Journey to Action", U.S. GSK's "mercury program" and so on into the third terminal in the rural market in the journey to find a sea of blue.

Now, rural drug market, due to effects of fatigue, has become more and more popular.

Now, rural drug market, due to effects of fat cheese, no business not for the heart, manufacturers there have been continued down the focus of pharmaceutical marketing phenomenon. Obviously, today is that many pharmaceutical companies homogeneous competition eroded profit chain to share space, so they took a step to the end of some pharmaceutical companies, the Government can, through compression channels to improve the level of channel profit status ; the other hand, sales + service business through the Government can, through compression channels to improve the level of channel profit status ; the other hand, sales + service business through the channel to form a unique value chain competitive advantage, the pressure in the face of grim reality, many The pressure in the face of grim reality, many pharmaceutical companies, such as not-for-brains, you can Ting Dezhu it?

Third, the full integration of resources

Pharmaceutical industry, especially SMEs, to

Third, the full integration of resources

Pharmaceutical industry, especially SMEs, to compete in the market is not keen to be swallowed, need flexible mechanisms, innovative thinking to address the changing The Blue Ocean Marketing Consultants Colombian intelligence agencies do this out of three prescriptions:

Prescription one or small pharmaceutical companies to share resources, a lot of them are not the same. Pharmaceutical companies to share resources, a lot of money if the backlog in fixed assets, the corresponding R & D will bring a lot of pressure and risks. At this time, should take the initiative to create opportunities for multi-seeking strength, brand sound as the other major pharmaceutical companies processing base, activate idle equipment, and to create a new brand name. companies processing base, activate idle equipment, so as to change the survival predicament. In fact, many enterprises are in need of such well-known OEM and OEM production to enhance competitive advantage, to complete the value chain remodeling and recycling, and then by mutual agreement or by the other party to the acquisition, merger, and reorganization. In fact, many enterprises are in need of such well-known OEM and OEM production to enhance competitive advantage, to complete the value chain remodeling and recycling, and then by mutual agreement or by the other party to the acquisition, merger, reorganization of the way to small and medium sized pharmaceutical companies into the Group's overall strategy of operating system, small pharmaceutical companies to retain the original technology and talent advantages, flexible production volume is small, effective strength and high cost of a single pharmaceutical company. effective strength and high cost of a single species, in order to maximize the target market segments to meet consumer demand, thereby to achieve for large enterprises to add specialized support services and energy efficiency.

Prescription II, ferreting out potential. Medium and small pharmaceutical companies with some up-scale, about the size of the market and the size of the market. Medium and small pharmaceutical companies with some up-scale, about the credibility of agents, distributors, the two sides complement each other, what they want, with the other's capital, networks, channels, and so the market does not have its own advantages, specifically specializing in the production and strictly ensuring quality of production, outsourcing, and the use of the market. ensure quality of production, outsourcing marketing is also carried out for each other OEM in order to save costs, reduce market risk and fully tap their

Prescription 3, leveraging each other. Several small pharmaceutical companies to leveraging each other and establish a strategic development concept. Only a small investment each, with its matching technology, business, logistics and other resources horizontal ties, information sharing, channel communion and risks. Only a small investment each, with its matching technology, business, logistics and other resources horizontal ties, information sharing, channel communion and risks to staff distribution and use of organic and reasonable, so that clear objectives conducive to the regional stand firm in the economy, the greatest degree of reduction of waste of resources.